: 2nd Annual Oligonucleotides Chemistry & Therapeutics Europe Congress

2nd Annual Oligonucleotides Chemistry & Therapeutics Europe Congress

September 2024 | Amsterdam, Netherlands
2nd Annual
Oligonucleotides Chemistry & Therapeutics Europe CongressSeptember 2024 | Amsterdam, Netherlands​

Cutting-edge oligo research & therapeutic development to advance innovation and knowledge-share. From new technologies
through to therapeutic success stories, do not miss out on joining us to stay at the forefront of research.

The Oligonucleotides Chemistry & Therapeutics Europe Congress includes...

  • Discuss the latest innovations in oligo chemistry & targeted delivery approaches. Presentation will cover aptamer technologies, antisense therapies, modification & nucleoside chemistry as well as peptide-oligo conjugation methods & strategies  
  • Discover collaborative solutions to oligonucleotides therapeutics analytics – gain invaluable insights into cell-based assay development, in vitro and in vivo imaging as well as advanced computational approaches such as AI/ML and CRISPR/Cas systems  
  • Gain a comprehensive understanding of oligo & antisense therapeutics case studies & commercialisation approaches. Tap into safety & efficacy development, antisense clinical development and new nucleotides  
  • Take a deep dive into oligonucleotides therapeutics proof of concepts & new innovations. Key opinion leaders will discuss clinical case studies in gene therapy and therapeutic therapies using oligonucleotides as well as mRNA targeting drugs  

2024 Agenda at a Glance

Day One 

  • Oligo synthesis
  • siRNA/RNAi
  • Aptamer technologies
  • Antisense therapies
  • Modification chemistry
  • Nucleoside chemistry
  • Peptide-oligo conjugation
       » Site-specific bioconjugation 
  • Cell-based assay development
  • In vitro and in vivo imaging
  • Computational approaches, methods & tools
       » AI/ML
       » Gene editors
       » CRISPR/Cas systems
       » Guide-RNA design
  • Rapid screening analytical methods for oligonucleotides
  • Stability testing

Day Two

Part 1 –

  • Preclinical development
    o Safety assessment
    o Efficacy assessment
  • Clinical development
    o Antisense oligonucleotides
    o siRNA therapeutics
  • Commercialization
  • New nucleotides


Part 2 –

Oligonucleotides Therapeutics Proof of Concepts & New Innovations

  • Clinical case studies in gene therapy and therapeutic therapies using oligonucleotides
  • Therapeutic mRNA editing for genetic disorders
  • mRNA targeting drugs